Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | STAMBP | O95630 | 1/20 | 0.50 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213879 | 0.87 | L3MBTL1 (0.69) | L3MBTL1CXCR4SMN1; SMN2LMNACYP3A4 | |
| SCHEMBL5083115 | 0.84 | TSHR (0.71) | CXCR4SMN1; SMN2LMNACYP3A4MAPK14 | |
| SCHEMBL5077115 | 0.83 | HPGDS (0.67) | L3MBTL1SMN1; SMN2LMNAROCK2 | |
| SCHEMBL5079750 | 0.83 | CXCR4 (0.58) | L3MBTL1CXCR4SMN1; SMN2ROCK2TSHR | |
| SCHEMBL6077802 | 0.83 | L3MBTL1 (0.77) | L3MBTL1CXCR4SMN1; SMN2LMNACYP3A4 | |
| SCHEMBL5078937 | 0.83 | EPHX2 (0.60) | L3MBTL1CXCR4SMN1; SMN2MAPK14ROCK2 | |
| SCHEMBL1569192 | 0.82 | L3MBTL1 (1.00) | L3MBTL1SMN1; SMN2LMNACYP3A4MAPK14 | |
| SCHEMBL20804634 | 0.81 | L3MBTL1 (0.70) | L3MBTL1CXCR4SMN1; SMN2LMNACYP3A4 | |
| SCHEMBL12191062 | 0.81 | HDAC1 (0.67) | L3MBTL1SMN1; SMN2STAMBPCOPS5 | |
| SCHEMBL31095752 | 0.80 | CXCR4 (1.00) | L3MBTL1CXCR4SMN1; SMN2ROCK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101627019-B | Bicyclic pyrimidinones and uses thereof | AVEXA LTD | 2013-07-10 | — | — | CN | disclosed |
| CN-101880280-A | Bicyclic pyrimidinones and uses thereof | SHANGHAI INST ORGANIC CHEM | 2010-11-10 | — | — | CN | disclosed |
| CN-101627019-A | Bicyclic pyrimidinones and uses thereof | AVEXA LTD | 2010-01-13 | — | — | CN | disclosed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | L3MBTL1 4731/4885CXCR4 72/4885SMN1; SMN2 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.